CUE · Cue Biopharma, Inc.

This filing represents a pivotal strategic inflection for Cue Biopharma, transforming it from a preclinical platform company into a clinical-stage biopharmaceutical enterprise with two distinct therapeutic modalities: a novel anti-IgE antibody (Ascendant-221) and its proprietary Immuno-STAT® platform (CUE-401). The $15 million upfront payment and substantial milestone structure—particularly the $205 million contingent on Phase 2 data—signal strong confidence in Ascendant-221’s dual mechanism of action, which combines picomolar IgE neutralization with CD23-mediated suppression of new IgE synthesis. This approach targets a key limitation of current anti-IgE therapies: inadequate control in high-IgE patients and frequent dosing requirements. The concurrent $30 million private placement provides critical near-term capital to fund the planned global Phase 2b trial in food allergy, expected to initiate after the anticipated H2 2026 readout from Ascendant Health’s ongoing CSU study. The appointment of Dr. Shao-Lee Lin—a seasoned immunology executive with prior CEO roles at ACELYRIN and AZEO BIO—directly addresses investor concerns about execution capability, as her compensation package and equity inducement plan are explicitly structured to align her incentives with long-term value creation and pipeline advancement. Collectively, these actions de-risk the company’s go-forward strategy by adding a near-term clinical catalyst, securing non-dilutive funding through milestone-linked payments, and installing proven leadership—making this a HIGH materiality event that fundamentally reshapes Cue’s investment profile.